Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 5 Rectal Fistula, CTCAE"
Page 1
Neoadjuvant chemoradiotherapy for locally advanced rectal cancer with peritumoral abscesses and fistulas.
Gordeyev S, Ivanov V, Fedianin M, Chernikh M, Kozlov N, Petrov L, Erygin D, Gridasov I, Kaushanskiy V, Feoktistov D, Mamedli Z. Gordeyev S, et al. Strahlenther Onkol. 2022 Feb;198(2):201-208. doi: 10.1007/s00066-021-01878-y. Epub 2021 Nov 25. Strahlenther Onkol. 2022. PMID: 34825253
All patients received 50-54 Gy of conventionally fractionated RT with concurrent chemotherapy. Primary endpoint was grade 3-5 toxicity (by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE). ...No patients developed grade …
All patients received 50-54 Gy of conventionally fractionated RT with concurrent chemotherapy. Primary endpoint was grade 3-5 …
Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study.
Mazeron R, Fokdal LU, Kirchheiner K, Georg P, Jastaniyah N, Šegedin B, Mahantshetty U, Hoskin P, Jürgenliemk-Schulz I, Kirisits C, Lindegaard JC, Dörr W, Haie-Meder C, Tanderup K, Pötter R; EMBRACE collaborative group. Mazeron R, et al. Radiother Oncol. 2016 Sep;120(3):412-419. doi: 10.1016/j.radonc.2016.06.006. Epub 2016 Jul 7. Radiother Oncol. 2016. PMID: 27396811
After sorting patients according to 6 [Formula: see text] levels, less favorable outcome was observed in the high dose subgroups, for bleeding, proctitis, fistula, and overall rectal morbidity. A [Formula: see text] 75Gy was associated with a 12.5% ris …
After sorting patients according to 6 [Formula: see text] levels, less favorable outcome was observed in the high dose subgroups, for …
Irreversible Electroporation to Treat Malignant Tumor Recurrences Within the Pelvic Cavity: A Case Series.
Vroomen LGPH, Scheffer HJ, Melenhorst MCAM, van Grieken N, van den Tol MP, Meijerink MR. Vroomen LGPH, et al. Cardiovasc Intervent Radiol. 2017 Oct;40(10):1631-1640. doi: 10.1007/s00270-017-1657-6. Epub 2017 May 3. Cardiovasc Intervent Radiol. 2017. PMID: 28470395 Free PMC article.
Median longest tumor diameter was 3.7 cm (range 1.2-7.0). One CTCAE grade III adverse event (hemorrhage) and eight CTCAE grade II complications occurred in 6/8 patients: vagino-tumoral fistula (n = 1), lower limb motor loss (n = 3; PNI type II) …
Median longest tumor diameter was 3.7 cm (range 1.2-7.0). One CTCAE grade III adverse event (hemorrhage) and eight CTCAE …